Seed funding: Anaveon, Emergence Therapeutics, Endoron Medical, SyMap Medical, HypnoVR, Kinarus

Switzerland: Kinarus, a Swiss clinical-stage biopharmaceutical company, has been awarded a Sfr7m (US$7.62m) grant from the Swiss Federal Funding Programme for Covid-19 Medicines. Kinarus is conducting two clinical studies of KIN001 in Covid-19; KINETIC, a randomised placebo-controlled trial of KIN001 in hospitalized Covid patients, and KIN001-204, a randomised placebo-controlled trial in Covid patients with mild-moderate…

You must be a HMI Subscriber to view this content.

Subscribe Now »